Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (8567)	1/30/2002 11:13:00 AM
From: Cal Gary	Read Replies (3) \| Respond to of 14101

Village people and The One Need some help here. Clipped the following from the OXOChemie.com website. It helps to review and put the whole OXO empire into view and attempt to sort out its org structure and guess at its ownership structure. DMX is wise to spend its sweet time in the acquisition. Acquisition is for the Swiss based OXO Chemie AG, but how about the German plant and German interest? OXO Chemie has expanded to create a worldwide presence since its founding in 1986 by Dr. Friedrich-Wilhelm Kühne, a scientist with more than 35 years of experience in research and development in the pharmaceutical industry and medical field. A Swiss-based firm, OXO Chemie holds worldwide patents for WF10 except for Germany, where separate licensure and all manufacturing facilities are maintained. Key research is conducted at OXO Chemie sites in Wanzleben, Germany, Bangkok, Thailand, and San Francisco, California. ------------- DMX's inaugural equity investment in OXO was 1996 and held 20% interest in 1997. Founded in October 1997, OXO Chemie Inc. is an independent pharmaceutical organization based in San Francisco, California. The Company is engaged in the management of clinical trials for its Swiss parent company, OXO Chemie AG. The OXO Chemie Group is active in the field of Life Sciences and offers specific know-how in macrophage regulation, in addition to the medical treatment of diseases resulting from dysfunction of macrophages. The core competence of the company is completed by the ability to assess the efficacy of therapy at the gene level. Restoring confidence. The INC's mandate. OXO Chemie designs, monitors and analyzes clinical trials in order to achieve FDA approval of a novel immune regulating compound in the field of life-threatening human diseases, including HIV/AIDS, HCV and other chronic infectious and inflammatory diseases. We are looking for key personnel with great attitude to help us in this exciting effort. -------------- Oh oh, perhaps this is the problem. Its a robot, its a ... Technology. LOL. DMX to the rescue?! For the sizable U.S. market, the OXO Chemie Group is actively developing WF10 in the U.S. drug development process. With automated project management and other progressive techniques, management of the company and its resources gets maximum efficiency. One would think, after reading this, they've got their ducks in line from the beginning. Gathering the data for the analysis would be a slam dunk. So why did RK paint such a bleak picture? Hmmm. -------------- OXO Chemie BOD. I believe its the 'AG' but could be 'INC'. Can anyone confirm or refute?? This is important! An aside: Michael Lehmann, J.D. -- Is he one of the Lehmann brothers? One can hopes, <g> OXO Chemie Board of Directors Friedrich-Wilhelm Kühne, Ph.D. Chairman Founder of OXO Chemie Group Rebecca Keeler President and Chief Executive Officer Dimethaid Research Inc. Toronto, Canada Michael Lehmann, J.D. Founding Partner of Lehmann and Neunhoeffer Stuttgart, Germany Yvo Schnarrenberger Founding Partner of Globalgist S.A. Fribourg, Switzerland --------------------------------------- Now a tangent. And speculative at that. The German Connection. Clipped this from a BRA NR. And guess who is down the street?? Merck KGaA, of Darmstadt, Germany. Merck KGaA, is the world's oldest pharmaceutical company and a leader in cancer research. It has created, or licensed-in a wide range of novel products. The ocology portfolio of Merck KGaA is based on four technology platforms - monoclonal antibodies, vaccines, immunocytokines and angiogenesis inhibitors. Time to head back to Yahoo. Plug in the coordinates for a new destination, Merck thread. Engage. Have a great day.